Paper Details

  1. Home
  2. Paper Details

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

Author: FraserGraeme L, KrollRobin, LedermanSamuel, LeeMisun, RamaelSteven, SantoroNanette, SkillernLaurence, WaldbaumArthur

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of menopausal vasomotor symptoms (VMS), which may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons.
Paper Details　
Original Abstract of the Article :
Menopausal vasomotor symptoms (VMS) may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32102086

データ提供：米国国立医学図書館（NLM）

Fezolinetant: A Non-Hormonal Approach for Menopausal Vasomotor Symptoms

This phase 2b study investigates the potential of fezolinetant, a selective neurokinin 3 receptor antagonist, as a non-hormonal treatment option for managing vasomotor symptoms (VMS) associated with menopause. VMS, such as hot flashes, are thought to result from alterations in thermoregulation within brain regions innervated by neurokinin 3 receptor-expressing neurons. The researchers conducted a randomized, placebo-controlled, double-blind study, evaluating the efficacy of fezolinetant at various dosages in women experiencing VMS.

Fezolinetant Shows Promise as a Non-Hormonal VMS Treatment

The study demonstrated that fezolinetant, at specific dosages, effectively reduced the frequency and severity of VMS, offering a potential non-hormonal treatment option for women experiencing these symptoms. The researchers observed a dose-dependent effect, with higher doses generally associated with greater reductions in VMS. This study provides a promising avenue for exploring non-hormonal therapies for menopausal symptoms.

Finding Relief From the Heat of Menopause

Imagine the desert sun beating down, representing the intense heat of menopausal vasomotor symptoms. This research offers a refreshing breeze in the form of fezolinetant, a potential non-hormonal solution for managing these uncomfortable symptoms. It highlights the ongoing search for effective and safe treatment options for women navigating the challenges of menopause.

Dr.Camel's Conclusion

This study provides a promising glimpse into the potential of fezolinetant as a non-hormonal treatment option for menopausal VMS. Just as a desert traveler seeks shade from the scorching sun, women experiencing VMS can find relief through the potential of fezolinetant. This research emphasizes the ongoing pursuit of innovative therapies for women's health, offering hope for a more comfortable and fulfilling menopausal experience.

Date :
  1. Date Completed 2020-12-31
  2. Date Revised 2022-10-05
Further Info :

Pubmed ID

32102086

DOI: Digital Object Identifier

00042192-202004000-00004

Related Literature

Article Analysis
・Effects of fezolinetant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.